{'52WeekChange': -0.3703704,
 'SandP52WeekChange': 0.0644362,
 'address1': '3150 Almaden Expressway',
 'address2': 'Suite 250',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.92,
 'askSize': 1000,
 'averageDailyVolume10Day': 216612,
 'averageVolume': 439468,
 'averageVolume10days': 216612,
 'beta': 1.67507,
 'beta3Year': None,
 'bid': 2.86,
 'bidSize': 2200,
 'bookValue': 0.246,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Jose',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.9572,
 'dayLow': 2.86,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.361,
 'enterpriseToRevenue': None,
 'enterpriseValue': 60509108,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.684,
 'fiftyTwoWeekHigh': 4.97,
 'fiftyTwoWeekLow': 1.33,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 21692284,
 'forwardEps': -0.52,
 'forwardPE': -5.5576925,
 'fromCurrency': None,
 'fullTimeEmployees': 7,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.05895,
 'heldPercentInstitutions': 0.06651,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1572480000,
 'lastMarket': None,
 'lastSplitDate': 1476748800,
 'lastSplitFactor': '1:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/anixa.com',
 'longBusinessSummary': 'Anixa Biosciences, Inc., a biotechnology company, '
                        'develops diagnostics and therapeutics to diagnose, '
                        'treat, and prevent cancer. The company is developing '
                        'the Cchek platform, a series of non-invasive blood '
                        'tests for the early detection of cancer, which is '
                        "based on the body's immune response to the presence "
                        'of a malignancy. It is also developing a vaccine '
                        'against triple negative breast cancer; and chimeric '
                        'endocrine receptor T-cell technology focused on '
                        'treating ovarian cancer. Anixa Biosciences, Inc. has '
                        'a collaboration with Urology San Antonio, P.A. and '
                        'Idaho Urologic Institute, PA for the development of '
                        'Cchek, a liquid biopsy technology; and with OntoChem '
                        'GmbH to develop novel Covid-19 therapeutics. The '
                        'company was formerly known as ITUS Corporation and '
                        'changed its name to Anixa Biosciences, Inc. in '
                        'October 2018. Anixa Biosciences, Inc. was founded in '
                        '1982 and is based in San Jose, California.',
 'longName': 'Anixa Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 67976560,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_263802',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1588204800,
 'navPrice': None,
 'netIncomeToCommon': -9460157,
 'nextFiscalYearEnd': 1635638400,
 'open': 2.86,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '408 708 9808',
 'previousClose': 2.86,
 'priceHint': 4,
 'priceToBook': 11.747968,
 'priceToSalesTrailing12Months': 'Infinity',
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.9572,
 'regularMarketDayLow': 2.86,
 'regularMarketOpen': 2.86,
 'regularMarketPreviousClose': 2.86,
 'regularMarketPrice': 2.86,
 'regularMarketVolume': 126650,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 23521300,
 'sharesPercentSharesOut': 0.0561,
 'sharesShort': 1318685,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1141315,
 'shortName': 'Anixa Biosciences, Inc.',
 'shortPercentOfFloat': 0.0637,
 'shortRatio': 3.2,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ANIX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.46,
 'twoHundredDayAverage': 2.548633,
 'volume': 126650,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.anixa.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '95118'}